Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
It has been reported that radiation therapy followed by PCV chemotherapy (procarbazine,
lomustine and vincristine) could improve progression-free survival (PFS) and overall survival
(OS) in patients with high-risk WHO grade 2 gliomas after surgery. However, procarbazine is
not available in China. In clinical practice, Chinese doctors often use radiotherapy combined
with temozolomide to treat these patients, though large-scale prospective studies are
lacking. This trial aims to confirm whether RT combined with temozolomide can improve PFS and
OS in patients with high-risk low-grade gliomas.